RxDoctor Payments Data

Lawrence Williams, MD

Internal Medicine · Columbus, GANPI 1336140052

Payments from drug & device makers

$11,796in general payments, 2019–2025

Across 778 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$757
  • Astellas Pharma US Inc$744
  • Amgen$595
  • plus $6K from 47 others

What the payments were for

  • Food & beverage$11,790100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,796 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$193,610
Medicare patients
315
Services billed
7,643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin165$150,516
RybelsusSemaglutide72$92,229
FarxigaDapagliflozin Propanediol96$86,857
JanuviaSitagliptin Phosphate73$74,509
MounjaroTirzepatide64$71,026
EliquisApixaban67$68,877
XareltoRivaroxaban38$40,857
LinzessLinaclotide36$26,695
VraylarCariprazine Hcl19$26,395
Tresiba Flextouch U-100Insulin Degludec27$24,458
TrulicityDulaglutide13$19,126
OzempicSemaglutide20$18,137
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$17,774
EntrestoSacubitril/Valsartan17$17,063
SymbicortBudesonide/Formoterol Fumarate29$15,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$258$165,273181 claims
Novo NordiskRybelsus, Ozempic$1,465$110,36692 claims
AstraZenecaFarxiga, Symbicort$757$101,930125 claims
Lilly USA, LLCMounjaro, Trulicity$1,045$90,15377 claims
MerckJanuvia, Janumet$140$80,56584 claims
PfizerEliquis$410$68,87767 claims
AbbVieLinzess, Vraylar$1,342$53,09055 claims
Johnson & JohnsonXarelto, Invokana$291$50,63149 claims
GSKTrelegy Ellipta, Incruse Ellipta$198$23,45332 claims
NovartisEntresto$572$17,06317 claims
BayerKerendia$467$9,49815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →